## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.3% in mid entry zone (3.0-6.0%), top 5% cross-sectional ranking. Short-term MRS_5 (2.2%) confirms momentum alignment. Outperforming sector by 4.9%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.34)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky**
- Source: WJBF | 20251217T000854 | Bearish | Relevance: 100%
- Levi & Korsinsky LLP has filed a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) for alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter, which led to a significant stock price decline after disappointing Q4 2024 financial results and 2025 guidance. Shareholders who suffered losses are encouraged to contact the firm to learn about their rights to recovery before June 3, 2025.

**2. Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20251217T120828 | Neutral | Relevance: 100%
- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026. The presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET and will be available via live webcast and an archived version on the company's investor relations website.

**3. Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back**
- Source: The Globe and Mail | 20251216T160825 | Bullish | Relevance: 100%
- Viatris Inc. has been recognized as one of the 2025 Best Workplaces™ in Ontario and for Giving Back in Canada. These awards highlight Viatris's dedication to creating a positive work environment where colleagues feel valued and engaged, as well as the company's commitment to meaningful community involvement.

**4. Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: StreetInsider | 20251217T120252 | Neutral | Relevance: 97%
- Viatris Inc. announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026. The presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET, with a live webcast available on the company's investor relations website. An archived version will also be accessible for a limited time after the event.

**5. Is FDA‑Cleared U.S.‑Made Teriparatide Pen Altering The Investment Case For Amphastar Pharmaceuticals (AMPH)?**
- Source: Simply Wall Street | 20251216T080843 | Neutral | Relevance: 63%
- Amphastar Pharmaceuticals recently secured FDA approval for its U.S.-made teriparatide injection prefilled pen, a generic equivalent to Eli Lilly’s FORTEO, targeting a US$585 million market. This move underscores the company's shift towards higher-value products and domestic production, which could be critical for its profitability amidst recent earnings pressure. The success of this launch will test Amphastar's ability to leverage expanding domestic capacity to improve financial performance and reduce reliance on older offerings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.8x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.8B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.68 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.8 |
| Current P/E | 5.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 95th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. Outperforming sector by 4.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.29% (CS: 95) | Strong |
| RSI_14 | 72.9 | Overbought |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.081x | Above |
| vs SMA50 | 1.122x | Above |
| vs SMA200 | 1.253x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $11.94
- **Stop Loss:** $11.34 (5.0% risk)
- **Target:** $12.84 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1583
- **Position Value:** $18,901.02
- **Portfolio %:** 18.90%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*